Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.42 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
| ▸ | VDR | P11473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13196125 | 0.92 | ALDH1A1 (0.43) | ALDH1A1TSHRMAPK1TDP1ZDHHC20 | |
| SCHEMBL20987889 | 0.82 | ALDH1A1 (0.45) | ALDH1A1TSHRMAPK1TDP1ZDHHC20 | |
| SCHEMBL12264492 | 0.79 | ZDHHC20 (0.48) | ALDH1A1TSHRMAPK1TDP1ZDHHC20 | |
| SCHEMBL24599175 | 0.77 | SMN1; SMN2 (0.40) | ALDH1A1TSHRGAA | |
| SCHEMBL24599179 | 0.77 | TGM2 (0.37) | ALDH1A1CYP2C19TGM2 | |
| Methyl Alcohol SCHEMBL8855368 | 0.77 | — | — | |
| Ethane SCHEMBL9809196 | 0.77 | — | — | |
| SCHEMBL17368478 | 0.76 | ZDHHC20 (0.55) | ALDH1A1TSHRMAPK1TDP1ZDHHC20 | |
| SCHEMBL1488043 | 0.76 | TSHR (0.65) | ALDH1A1TSHRMAPK1TDP1ZDHHC20 | |
| SCHEMBL25806 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029791-B2 | Therapeutic conjugates | TOTUS MEDICINES INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12029791-B2 | Therapeutic conjugates | TOTUS MEDICINES INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20220387603-A1 | THERAPEUTIC CONJUGATES | TOTUS MEDICINES INC. | 2022-12-08 | — | — | US | disclosed |
| US-20220211855-A1 | THERAPEUTIC CONJUGATES | TOTUS MEDICINES INC. | 2022-07-07 | — | — | US | disclosed |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-09 | — | — | US | disclosed |
| US-9980964-B2 | ERK inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-05-29 | — | — | US | disclosed |
| US-9796700-B2 | ERK inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2017-10-24 | — | — | US | disclosed |
| US-20170210729-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-07-27 | — | — | US | disclosed |
| US-20170137406-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-05-18 | — | — | US | disclosed |
| US-9561228-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-20120258967-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137406-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | ALDH1A1 2838/4885TSHR 3596/4885MAPK1 8/4885 |
| US-12029791-B2 | Therapeutic conjugates | CD47, CD44, EPCAM | ALDH1A1 1307/4885TSHR 1880/4885MAPK1 4779/4885 |
| US-20220387603-A1 | THERAPEUTIC CONJUGATES | CD47, CD44, EPCAM | ALDH1A1 1307/4885TSHR 1880/4885MAPK1 4779/4885 |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | ALDH1A1 4078/4885TSHR 4677/4885MAPK1 345/4885 |
| US-20120258967-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PIK3CA, PIK3CB, PIK3C2B | ALDH1A1 4394/4885TSHR 4020/4885MAPK1 423/4885 |
| US-20220211855-A1 | THERAPEUTIC CONJUGATES | CD47, CD44, EPCAM | ALDH1A1 1307/4885TSHR 1880/4885MAPK1 4779/4885 |
| US-20170210729-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | ALDH1A1 2838/4885TSHR 3596/4885MAPK1 8/4885 |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | ALDH1A1 4078/4885TSHR 4677/4885MAPK1 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.